Regelgeving en recht · 30-10-20261 min lezen
Schedules of Controlled Substances: Placement of Centanafadine in Schedule III
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and…